Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 29, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Global Mizuho Investor Conference 2017

EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
November 28, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4

EMERYVILLE, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
November 21, 2017 08:00 ET | Source: Zogenix, Inc.

New Data from Zogenix’s Phase 3 Trial of ZX008 in Dravet Syndrome (Study 1) and Findings on Disease Impact to be Presented at 71st American Epilepsy Society Annual Meeting

Updated Results of Phase 2 Study of ZX008 in Lennox Gastaut Syndrome to be Presented Data Demonstrating Disease Burden and Negative Impact on Quality of Life of Patients and Families Will Also be...
November 14, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Present at Stifel 2017 Healthcare Conference

EMERYVILLE, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
November 07, 2017 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results

During the third quarter, the Company announced positive top-line results from its Phase 3 Study 1 of ZX008 in patients with Dravet syndromeStudy 1 met primary endpoint of reduction in frequency of...
October 31, 2017 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7

EMERYVILLE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
October 19, 2017 02:00 ET | Source: Zogenix, Inc.

High Seizure Frequency in Children with Dravet Syndrome Negatively Impacts Quality of Life, New International Caregiver Survey Finds

Global survey of 584 caregivers of children, young adults and adults with Dravet illustrates the detrimental effect of debilitating, frequent seizures on quality of life and co-morbidities Results...
October 16, 2017 08:00 ET | Source: Zogenix, Inc.

Interim Survey Results Demonstrate Impact on Siblings of Children Suffering from Severe Epilepsy

Findings Presented by Zogenix at the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C. EMERYVILLE, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc....
October 05, 2017 16:35 ET | Source: Zogenix, Inc.

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
October 02, 2017 20:05 ET | Source: Zogenix, Inc.

Zogenix Prices Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right